Copyright
©2014 Baishideng Publishing Group Co.
World J Hepatol. Apr 27, 2014; 6(4): 160-168
Published online Apr 27, 2014. doi: 10.4254/wjh.v6.i4.160
Published online Apr 27, 2014. doi: 10.4254/wjh.v6.i4.160
Table 1 Classification of drug-induced autoimmune liver disease
| AIH with DILI | Patients with known AIH AIH quiescent: the drug may be the trigger of a new bout AIH under IS or corticosteroids treatment: Reactivation of known AIH upon intro duction of a newdrug (very difficult to demonstrate a causal relationship as it might be coincidental Often advanced fibrosis on histology |
| DI-AIH | Patients with a low grade disease not diagnosed before or predisposition to AIH Drug produce an immune reaction that lead to a chronic process: Perpetuating the AIH Permanent need of IS Habitually typical HLA-DR associated |
| IM-DILI (Autoimmune hypersensitivity) | Fever, eosinophilia, lymphadenopathy, rush Indistinguishable from true AIH: Mandatory IS treatment Frequently spontaneous remission after drug cessation Usually complete response to treatment and sustained remission without relapse It is the most frequent drug-induced immune process in the liver attributable to drugs |
| Mixed autoimmune type | Patients with mixed clinical features of DI-AIH and IM-DILI Complete response to IS treatment but with chronic course after withdrawal Patients under IS treatment for another autoimmune disease. Withdraw IS drugs is not possible. Remission cannot be evaluated |
| DILI with positive autoantibodies | Patients with positive autoantibodies The probability of developing DIAILD increases in second DILI episodes indepe dently of the causal agent |
Table 2 Elements to be reported when a case of drug- induced autoimmune liver disease is suspected
| Previously obtained ANA |
| Evolution: |
| During the treatment with the suspicious drug |
| After drug withdrawal |
| Check for the presence of HLA-DR: |
| HLA-DRB1*0301,0401,07,1301 |
| Drug type |
| Time to onset from the beginning of the treatment |
| AIH diagnosed: |
| During the course of treatment |
| After withdrawal of the drug |
| AIH scales for diagnosis |
| International autoimmune hepatitis group report (4) |
| Simplified score (5) |
| Previous DILI episodes |
| Response to corticosteroids |
| Autoimmune titres evolution |
| IgG values evolution |
Table 3 Drugs and drug-induced autoimmune liver disease
| Well stablished drugs: |
| Minocycline |
| Nitrofurantoin |
| Oxyphenisatin, alpha-methyl-dopa, clometacin. |
| Emerging drugs: |
| Statins |
| Biologics agents: |
| Infliximab |
| Others: adalimumab, etanercept, efalizumab, ipilimumab |
| Other drugs: |
| Less compelling association (infrequent reports): atomoxetine, diclofenac, fenofibrate, pemoline, phenprocoumon, dihydralazine, tielinic acid, benzarone |
- Citation: Castiella A, Zapata E, Lucena MI, Andrade RJ. Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. World J Hepatol 2014; 6(4): 160-168
- URL: https://www.wjgnet.com/1948-5182/full/v6/i4/160.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i4.160
